Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals.

The Open Virology Journal Pub Date : 2018-02-28 eCollection Date: 2018-01-01 DOI:10.2174/1874357901812010016

Ivan Schietroma, Giuseppe Corano Scheri, Claudia Pinacchio, Maura Statzu, Arnolfo Petruzziello, Vincenzo Vullo

{"title":"Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals.","authors":"Ivan Schietroma, Giuseppe Corano Scheri, Claudia Pinacchio, Maura Statzu, Arnolfo Petruzziello, Vincenzo Vullo","doi":"10.2174/1874357901812010016","DOIUrl":null,"url":null,"abstract":"Introduction: Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma.Explanation: Epidemiological studies have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of hepatocellular carcinoma (HCC), mainly through chronic inflammation, cell deaths, and proliferation. Despite the new direct-acting antiviral drugs (DAA's) being able to clear the HCV, HCC recurrence rate in these patients is still observed.Conclusion: In this review we highlighted some aspects that could be involved in the onset of HCV-induced HCC such as immune system, viral factors and host genetics factors.Moreover, we focused on some of the last reports about the effects of DAA's on the HCV clearance and their potential implications in HCC recurrence.","PeriodicalId":23111,"journal":{"name":"The Open Virology Journal","volume":"12 ","pages":"16-25"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1874357901812010016","citationCount":"25","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Virology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874357901812010016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 25

Abstract

Introduction: Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma.

Explanation: Epidemiological studies have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of hepatocellular carcinoma (HCC), mainly through chronic inflammation, cell deaths, and proliferation. Despite the new direct-acting antiviral drugs (DAA's) being able to clear the HCV, HCC recurrence rate in these patients is still observed.

Conclusion: In this review we highlighted some aspects that could be involved in the onset of HCV-induced HCC such as immune system, viral factors and host genetics factors.Moreover, we focused on some of the last reports about the effects of DAA's on the HCV clearance and their potential implications in HCC recurrence.

查看原文本刊更多论文

丙型肝炎病毒与肝细胞癌:直接作用抗病毒药物的发病机制和影响。

导读:全球范围内，慢性丙型肝炎病毒(HCV)感染人数在6400万至1.03亿之间，其中美国有460多万人，每年有15000多人死亡。慢性感染可导致肝硬化和肝细胞癌。解释:流行病学研究表明，持续感染丙型肝炎病毒(HCV)是发展为肝细胞癌(HCC)的主要危险因素，主要表现为慢性炎症、细胞死亡和增殖。尽管新的直接作用抗病毒药物(DAA’s)能够清除HCV，但这些患者的HCC复发率仍然存在。结论:在本综述中，我们强调了可能参与hcv诱导的HCC发病的一些方面，如免疫系统、病毒因素和宿主遗传因素。此外，我们关注了最近一些关于DAA对HCV清除率的影响及其在HCC复发中的潜在意义的报道。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Open Virology Journal

自引率

0.00%

发文量